Dr. Jacques-Pierre Moreau is a Venture Partner at ALCEA ADVISORS.
Dr. Moreau, a renowned and highly respected executive within the biopharma industry, has more than 30 years of experience in the Health and Life Sciences industry across the spectrum of drug discovery, development and commercialization.
Dr. Moreau is the co-founder of several successful biotech companies such as Biomeasure, ProteoThera and Provulis in Boston. He also contributes his scientific, technical, clinical and regulatory expertise to a leading European Investment Bank and to DBV (FR), Egalet (DNK) and HRA (FR).
Previously Chief Scientific Officer and a Member of the Executive Committee of Ipsen S.A, Dr. Moreau presided over the group R&D programs in Paris, London, Barcelona and Boston; and was an active contributor to Ipsen’s IPO in 2005 and to the spin-offs of Preglem (CH), Radius Health, Inc. (MA, U.S.A.), Functional Therapeutics (U.K./CH) and Rhythm Pharmaceuticals (MA, U.S.A.)
Dr. Moreau served as a Director at Dr. Reddy’s Laboratories Ltd (India), member of the Science, Technology, Strategy and Risk committees. He is also a former board member of Phytochemics, an Inventages Venture-funded company, and a former advisor to Nitto Denko & Teijin Pharmaceutical (Japan).
Dr. Moreau holds a Master’s degree in Physical Chemistry and was awarded a DSc from the University of Orleans, France based on Doctoral studies conducted at the Worcester Foundation for Experimental Biology (now part of U-Mass), followed by Post-doctoral studies at the École Polytechnique in Paris.